Weisheng Kang Secures Over RMB 100 Million Series A Funding to Advance Respiratory and Critical Care Solutions
VCBeat has learned at the earliest opportunity,Awakzon Medical (Jiangsu) Co., LTD (hereinafter referred to as "Awakzon"), an innovative enterprise specializing in high-end respiratory support, critical care equipment, and platform management, has recently obtainedOver RMB 100 Million in Series A Funding from SDIC Capital and Danlu Capital. The funds from this round will be used for the research and development, production, operations, team expansion, and overseas business expansion of the company’s full product line in the fields of respiratory care and critical care medicine.
It is reported that after completing a Pre-A financing round of tens of millions of RMB, Awakzon Medical has made smooth progress in the research and development of several new product pipelines. One year later, the company has once again secured a new round of financing.
Awakzon’s product portfolio includes innovative Extracorporeal Membrane Oxygenation (ECMO) systems, intelligent airway management systems, high-flow oxygen therapy devices, respiratory support systems, and mechanical ventilation equipment.With years of accumulated expertise in respiratory and critical care therapeutic products, Awakzon Medical leverages joint R&D of internationally leading advanced medical technologies to better address the shortcomings in China’s high-end medical equipment for respiratory and critical care.
Awakzon upholds the corporate mission of “Saving Lives, Creating Miracles,” dedicated to filling domestic gaps, leading with advanced international technologies, better meeting clinical needs, and benefiting human health.
SDIC Chuanghe is the professional fund-of-funds and industrial fund management arm of SDIC (State Development & Investment Corp.). It currently manages two national-level funds, two special projects funded by the central government, three regional industrial funds, and three market-oriented funds, with directly managed assets exceeding RMB 40 billion. Focusing on equity investment, venture capital, and fund investments in strategic emerging industries, it has over 100 direct investment portfolio companies and holds stakes in more than 180 funds. To date, it has supported over 3,000 innovative technology enterprises, making it the leading fund-of-funds manager in China in terms of the number of venture capital teams supported and the breadth of industry coverage. Under the advocacy of the National Development and Reform Commission, SDIC Chuanghe took the lead in establishing the National Venture Capital Service Alliance for Innovative Biomedicine, Artificial Intelligence, New Materials, and Cybersecurity. As a council member of the Asset Management Association of China, it continuously improves its investment ecosystem, harnesses the collective strength of mass entrepreneurship and innovation, and promotes the development of emerging industries.
Danlu Capital is a venture capital firm focused on the healthcare sector. Co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner of Fenxiang Investment Management, the firm has been deeply committed to the early-stage healthcare and wellness industry. It has systematically invested across multiple domains, including innovative medical technologies such as high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health, as well as innovative drugs and novel healthcare services.
Danlu Capital is committed to rewarding investors with strong performance and aims to leverage the power of capital to accelerate the R&D and commercialization of modern medical and pharmaceutical technologies, thereby improving the health and well-being of the general public. Our goal is to become a trusted, enduring, and premier healthcare fund management firm.